Revision and Appeal: Two Levels of Administrative Remedy
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Nicaragua provides two levels of administrative remedy against a rejection or cancellation decision: first a review (Revisión), then an appeal (Apelación). A review must be filed in writing with the ANRS unit that issued the decision within 10 working days of the rejection or cancellation being issued, and that unit replies within a maximum of 10 working days (Annex I, Article 16, of RA 0007/2025). A party dissatisfied with the review decision may appeal to the General Directorate of ANRS within 10 working days of notification of that decision, with the same maximum of 10 working days to reply (Article 17). Each level may be used only once, and once the appeal decision is issued the administrative route is exhausted.
2. Legal basis
The two remedies and their procedural rules are contained in Articles 16 and 17 of Annex I, with the sanctions reference in Article 18. The key provisions are set out below.
| Level | Instrument | Provision | Key point |
| Administrative decision | Administrative Resolution No. 0007/2025 (in force from 2025-05-02) | Annex I, Article 16, paragraphs 1 and 2 | A review may be filed against final acts; it must be submitted in writing to the ANRS unit that issued the rejection or cancellation, together with the case file |
| Administrative decision | Administrative Resolution No. 0007/2025 (in force from 2025-05-02) | Annex I, Article 16, paragraph 3 | Filing a review does not suspend execution of the act, although the competent unit may suspend it where it considers this necessary |
| Administrative decision | Administrative Resolution No. 0007/2025 (in force from 2025-05-02) | Annex I, Article 16, paragraphs 4 and 5 | Must be filed within 10 working days of the rejection or cancellation being issued in Karplus; the competent unit replies within a maximum of 10 working days; no further review lies against the review decision |
| Administrative decision | Administrative Resolution No. 0007/2025 (in force from 2025-05-02) | Annex I, Article 17, items 1 and 2 | An appeal may be filed with the unit that issued the challenged act or directly with the General Directorate of ANRS; it must be filed within 10 working days of notification of the review decision, with supporting documents |
| Administrative decision | Administrative Resolution No. 0007/2025 (in force from 2025-05-02) | Annex I, Article 17, items 3 and 4 | The competent unit replies within a maximum of 10 working days; no further appeal lies against the appeal decision, and the administrative route is deemed exhausted |
| Administrative decision | Administrative Resolution No. 0007/2025 (in force from 2025-05-02) | Annex I, Article 18 | Breaches are dealt with under Ley 1068 and Ley 423 and their regulations |
3. Expert insights
Insight 1: the two levels start from different points and cannot substitute for each other. The review runs 10 working days from the date the rejection or cancellation is issued in Karplus; the appeal runs 10 working days from the date the review decision is notified. Miscalculating the starting point forfeits the remedy outright.
Insight 2: non-suspension is the principle and suspension the exception. Article 16 states «La interposición del recurso no suspende la aplicación del acto, pero la instancia competente podrá suspenderlo si así lo considerase necesario» — filing the remedy does not suspend application of the act, but the competent body may suspend it if it considers this necessary. This means that while the remedy is pending the original decision, including a cancellation, continues in force: a cancelled registration is not automatically restored by filing a review.
Insight 3: each level is available only once, so the administrative route has just two steps. The final paragraph of Article 16 states «no podrá interponerse nuevo recurso de revisión», and item 4 of Article 17 states «no podrá interponerse nuevo recurso de apelación y se entenderá agotada la vía administrativa». There is no loop and no third level.
Insight 4: the appeal may be received by the original unit. Item 1 of Article 17 allows the appeal to be filed with the unit that issued the challenged act, which then forwards it to the General Directorate of ANRS together with the case file and its report. This design reduces jurisdictional disputes, but it also means the materials must pass through the original unit once.
Insight 5: Article 17 introduces the concept of qualified procedural acts. The term «actos de trámite cualificados» refers to acts that make it impossible for the procedure to continue, that decide the substantive issue in advance, or that cause a situation of no defence or irreparable harm; such acts may also be appealed directly. This leaves a remedy channel open for improper handling in the middle of a procedure, not only for final decisions.
Insight 6: remedies, re-filing and correction are three different routes with very different costs and timelines. After a rejection a party may correct within the correction window (cheapest), re-file with a new payment once the application has been cancelled (most expensive), or pursue review and appeal (intermediate in cost but uncertain in outcome). Which route to take depends on the stage at which the rejection occurred, the number of correction attempts remaining, and pressure from shipment schedules.
4. Practical recommendations
- On the day the rejection or cancellation is received, record the issue date in Karplus and schedule preparation of the review against 10 working days.
- Request suspension of execution in the review itself: Article 16 allows the competent unit to suspend where it considers this necessary, and absent a request the default is non-suspension.
- If the review is rejected, count the 10 working days for appeal from the date the review decision is notified, not from the original rejection.
- Prepare the appeal materials in two sets: where the appeal is filed with the original unit, that unit must forward it to the General Directorate together with the case file and report (Article 17, item 1).
- Build a cost comparison of correction, re-filing and remedies before deciding: correction is cheapest, re-filing most expensive, and remedies intermediate but uncertain.
- Improper handling in the middle of a procedure can also be challenged: where it meets the definition of a qualified procedural act, an appeal may be filed directly under Article 17.
5. Verification checklist
- □ Recorded the issue date of the rejection or cancellation in Karplus and scheduled review preparation against 10 working days
- □ Included a request for suspension of execution in the review (Article 16, paragraph 3)
- □ Counted the appeal deadline from the date of notification of the review decision, not from the original rejection
- □ Prepared the appeal materials for both channels, filing with the original unit and filing directly with the General Directorate
- □ Compared cost and duration across correction, re-filing and remedies before deciding
- □ Assessed whether improper handling mid-procedure qualifies as a qualified procedural act open to direct appeal
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Nicaraguan market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us